What are the precautions for capmatinib?

Capmatinib is a targeted therapy for the treatment of non-small cell lung cancer harboring mutations in MET exon 14. It helps patients control the spread of pathological cells by inhibiting MET tyrosine kinase, and has obtained good efficacy in clinical application.

What are the precautions for capmatinib?

Before using drugs for treatment, patients should understand the relevant precautions of drugs in detail, according to the drug instructions as follows:

1. Prevention of photosensitivity risk

Capmatinib may trigger photosensitivity, and patients are advised to avoid direct exposure to ultraviolet light as much as possible to reduce the associated risks.

2. Embryo-fetal toxicity and contraceptive recommendations

Patients should be advised that capmatinib may cause potential harm to the fetus and that effective contraception should be used during medication to avoid unwanted pregnancies.

What are the adverse effects of capmatinib?

Some patients will inevitably have some adverse reactions when using capmatinib, and patients should pay close attention to their own medication status to understand the following common adverse reactions:

1. Vomiting

Vomiting is the result of further development of nausea, which not only causes the patient to lose a lot of water and electrolytes, but can also cause complications such as esophageal damage, inflammation of the gastric mucosa, etc. Frequent vomiting can also lead to serious consequences such as dehydration and electrolyte imbalances.

2. Dyspnea

Dyspnea is one of the more serious manifestations of adverse drug reactions, which may be caused by a variety of factors such as drug-induced allergic reactions, lung damage, or cardiovascular reactions. Patients may experience uncomfortable symptoms such as strained breathing, shortness of breath, and chest tightness, which can be life-threatening in severe cases.

What drug interactions can occur with capmatinib?

According to the drug label, drug ingredients that can interact with capmatinib include:

CYP3A inducers have the effect of enhancing the activity of the CYP3A enzyme in the human body, which may lead to a significant reduction in blood concentrations of drugs that rely on CYP3A for metabolism, such as capmatinib. The decrease in blood concentration will in turn weaken the anti-tumor activity of capmatinib and affect the treatment effect. Patients are advised to avoid concomitant intake of CYP3A inducers during capmatinib use.

Such drugs and substances include, but are not limited to, the anti-tuberculosis drugs rifampicin and rifapentine, the anti-epileptic drugs phenytoin and carbamazepine, barbiturates, and herbs that induce CYP3A enzyme activity, such as St. John's wort.

[Warm tips] Patients need to undergo regular blood tests and monitoring of various visceral functions during the use of capmatinib, which can help to detect and deal with possible adverse reactions in time and ensure the smooth progress of the treatment process.